Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03131531

Bergamo Lymphoid Cancer Registry

This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hodgkin Lymphoma Hemic and Lymphatic Diseases Hodgkin Disease Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Non Hodgkin Lymphoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hematology and Bone Marrow Transplant Unit, A.O. Ospedale Papa Giovanni XXIII

Bergamo, 24127, Italy

Location status: Recruiting

About this study

Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients 18 years or older
  • Written informed consent
  • Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

Exclusion criteria

  • Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

Treatment and study plan

Patient Registry

Other

Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Primary outcomes

  1. Overall survival

    Time frame: 20 years

    Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics

Secondary outcomes

  1. Disease-free survival

    Time frame: 20 years

    Analyzed only for patients in complete response, as time from achievement of the complete response to relapse or death due to disease or acute toxicity of treatment, stratified according to intervention and baseline characteristics

  2. Progression-free survival

    Time frame: 20 years

    Analyzed for all patients, as time from diagnosis to progression of disease or death as a result of any cause, stratified according to intervention and baseline characteristics

  3. Biological correlative studies

    Time frame: 20 years

    Association between clinical and biologic characteristics

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

A.O. Ospedale Papa Giovanni XXIII

Other

Registry information

Important dates

Study start
2017
Primary completion
2027
Study completion
2037
First posted
Apr 27, 2017
Registry last updated
Mar 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.